0Q1N Stock Chart & Stats
$28.11
$0.00(0.00%)
At close: 4:00 PM EDT
$28.11
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$21.83 - $30.36
Previous CloseN/A
Volume86.00
Average Volume (3M)85.52K
Market Cap
$171.62B
Enterprise Value$190.23B
Total Cash (Recent Filing)$11.70B
Total Debt (Recent Filing)$63.19B
Price to Earnings (P/E)39.5
Beta0.91
Next Earnings
Nov 03, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.76
Shares Outstanding5,699,674,000
10 Day Avg. Volume124,109
30 Day Avg. Volume85,517
Financial Highlights & Ratios
PEG Ratio-4.33
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue2.99
Enterprise Value/Gross Profit4.19
Enterprise Value/Ebitda14.10
Forecast
1Y Price Target
$29.62Price Target Upside5.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)2.96
Revenue Forecast (FY)$62.25B
Bulls Say, Bears Say
Bulls Say
Diversified Commercial PortfolioGrowth from launched and acquired products, alongside expansion outside COVID products, indicates Pfizer is rebuilding a broader commercial base. Strong performance across Seagen assets, Padcev, NURTEC and Eliquis can support recurring revenue and reduce reliance on any single product over the next several quarters.
Pipeline And Innovation MomentumA productive development engine improves the probability of replenishing the portfolio as mature products face competition and exclusivity losses. Progress across oncology, obesity, immunology and ADC programs provides multiple avenues for future growth rather than depending on one therapeutic area or candidate.
Cost Savings And Operating DisciplineLarge, multi-year productivity initiatives can provide a durable offset to revenue pressure by improving the cost base and preserving investment capacity. Manufacturing optimization and realized savings may support margins, cash generation and continued funding for late-stage research and commercial launches.
Bears Say
Elevated Leverage During LOE TransitionA relatively high debt burden reduces financial flexibility while Pfizer approaches loss-of-exclusivity events that may pressure cash flow. Maintaining or increasing leverage could constrain business development, research investment and shareholder returns if product erosion is greater than expected.
Clinical Execution And Earnings VolatilityThe failed Phase III outcome highlights the inherent uncertainty of Pfizer’s pipeline and can weaken expected returns on research spending. Large impairments and reported losses also make earnings less predictable, complicating the recovery toward a more durable profit base.
Declining And Volatile COVID ContributionLower infection rates and utilization reduce a previously significant revenue stream, while demand remains tied to unpredictable public-health conditions. Continued COVID normalization can create a durable headwind to reported growth and require the broader portfolio to compensate for lost sales.
Pfizer News
0Q1N FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest share price was $21.83 and its highest was $30.36 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $171.62B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is Nov 03, 2026 which is in 11 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Aug 04, 2026. The company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.682 by $0.088.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer does not currently pay dividends.
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.73.
How many shares outstanding does Pfizer have?
Pfizer has 5,699,674,000 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.77 in its last earnings report, beating expectations of $0.682. Following the earnings report the stock price went up 2.046%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in GB:0Q1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pfizer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.62 (5.37% Upside)
$29.62 (5.37% Upside)
Blogger Sentiment
Bullish
GB:0Q1N Sentiment 83%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.69%
12-Months-Change
Fundamentals
Return on Equity
4.89%
Trailing 12-Months
Asset Growth
-2.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pfizer
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
0Q1N Company Deck
0Q1N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and strategic narrative: management beat Q2 revenue and adjusted EPS expectations, raised full-year revenue guidance, highlighted strong growth across launched and acquired products (notably Seagen assets, Padcev, NURTEC, and Eliquis), and outlined robust R&D progress (numerous readouts, pivotal starts and promising clinical data across obesity, oncology and immunology). At the same time, material near-term setbacks were disclosed: a Phase III SV miss that drove a $4.3 billion impairment and a GAAP loss, lower-than-expected COVID revenues (notably Paxlovid), removal of Oxbryta revenue from forecasts, and elevated near-term R&D spend. Management emphasized cost-savings initiatives (now targeting ~ $9.7B through 2029), maintained dividend commitments, and raised confidence in returning to growth by the end of the decade. Overall, positives (revenue/EPS beats, guidance raise, strong launched/acquired product growth, and significant pipeline progress) outweigh the material but specific negatives tied largely to one clinical readout and COVID variability.View all GB:0Q1N earnings summaries0Q1N Revenue Breakdown
97.79% Biopharma
0.00% PC1
0.00% Pfizer Ignite
2.21% Other business activities
0Q1N Stock 12 Month Forecast
Average Price Target
$29.62
▲(5.37% Upside)